Studies
| Title | Phase | Indication | Therapy | Sponsor | Status | |
|---|---|---|---|---|---|---|
| GAL-001: Adaptive Phase II in Refractory Melanoma | II | Refractory melanoma | NXC-101 (anti-PD-1 checkpoint inhibitor) | Galen Therapeutics | active | Open |
| Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. | II | Mild to Moderate Alzheimers Disease | Xanomeline | CDISCPILOT01 | completed | Open |
| A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer | III | Non-Small Cell Lung Cancer | Torivumab (programmed death receptor-1 blocking antibody) + platinum-based chemotherapy | Simulated Sponsor (synthetic data) | completed | Open |